Pipeline

Our pipeline highlights the vast potential of the ARTEMIS and E-ALPHA platforms to revolutionize the treatment of cancer. In addition to developing our own internal programs, we also collaborate with partners to bring ground-breaking immunotherapies to patients.

SOLID TUMORS

PARTNERS

PLATFORMS

CLINICAL TRIALS


ARYA2 – ET140203 T Cells in pediatric patients with AFP+ liver cancer

TARGET TYPE

SPECIAL DESIGNATIONS

Orphan Drug Designation
Fast Track Designation in pediatric hepatocellular carcinoma and hepatoblastoma
Rare Pediatric Disease Designation in pediatric hepatoblastoma

PLATFORMS

CLINICAL TRIALS

ARYA3 – ECT204 T Cells in adult patients with GPC3+ liver cancer

TARGET TYPE

SPECIAL DESIGNATIONS

Orphan Drug Designation

PLATFORMS

TARGET TYPE

PLATFORMS

TARGET TYPE

PLATFORMS

TARGET TYPE

PARTNERS

PLATFORMS

TARGET TYPE

PARTNERS

PLATFORMS

TARGET TYPE

PARTNERS

HEMATOLOGICAL

PLATFORMS

TARGET TYPE

PARTNERS

PLATFORMS

TARGET TYPE

PARTNERS

PLATFORMS

TARGET TYPE

PARTNERS

PLATFORMS

TARGET TYPE

Alexa Willson

CFO

Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.

Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.

Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.